Network pharmacology approach to investigate the molecular mechanism of DLBS2411 (Cinnamomum burmannii) as a gastritis treatment

Simple item page
dc.contributor.authorRustan, Jen_US
dc.contributor.authorYulandi, Aen_US
dc.contributor.authorTjandrawinata, RRen_US
dc.date.accessioned2024-11-30T11:21:20Z
dc.date.available2024-11-30T11:21:20Z
dc.date.issued2024-09
dc.description.abstractDLBS2411, a bioactive fraction of Cinnamomum burmannii, has been proven to exhibit its anti-ulcer properties through preclinical and clinical studies. However, the bioactive compounds, protein targets, and underlying molecular pathways are still poorly known. Therefore, network pharmacology was used in this study to understand the molecular mechanisms of DLBS2411 in treating gastritis. There were three stages in this investigation. First, the DLBS2411 compounds and targeted proteins associated with DLBS2411 and gastritis were gathered and examined. The subsequent stage involved constructing and analyzing the protein–protein interaction network. Then, molecular docking was employed to confirm the interaction between substances and proteins. This study found that most DLBS2411 compounds, including p-cymene, copaene, and cinnamaldehyde, were apparent in their effects on gastritis. These substances impacted several important target proteins, including PTGS1, PTGS2, 15-hydroxyprostaglandin dehydrogenase, NOS2, and ATPase H+/K+ transporting subunit alpha, which were associated with the mucosal protector and proton-pump inhibitor modes of action, consistent with earlier in vitro and in vivo studies. In addition, the molecular docking study revealed that the ligand-receptor binding activity had a good vina score, indicating stable ligand-protein complexes. Thus, it can be concluded that the proton pump inhibitor and mucosal protector were the key molecular pathways utilized by DLBS2411 to treat gastritis.en_US
dc.identifier.affiliationsFaculty of Biotechnology, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia; Dexa Laboratories of Biomolecular Sciences (DLBS), PT Dexa Medica, Cikarang, Indonesiaen_US
dc.identifier.affiliationsDexa Laboratories of Biomolecular Sciences (DLBS), PT Dexa Medica, Cikarang, Indonesiaen_US
dc.identifier.affiliationsFaculty of Biotechnology, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia; Dexa Laboratories of Biomolecular Sciences (DLBS), PT Dexa Medica, Cikarang, Indonesiaen_US
dc.identifier.citationRustan J, Yulandi A, Tjandrawinata RR. Network pharmacology approach to investigate the molecular mechanism of DLBS2411 (Cinnamomum burmannii) as a gastritis treatment. Journal of Applied Pharmaceutical Science. 2024 Sept; 14(9): 255-263en_US
dc.identifier.issn2231-3354
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/237705
dc.languageenen_US
dc.publisherOpen Science Publishers LLPen_US
dc.relation.issuenumber9en_US
dc.relation.volume14en_US
dc.source.urihttps://doi.org/10.7324/JAPS.2024.161905en_US
dc.subjectDLBS2411en_US
dc.subjectCinnamomum burmanniien_US
dc.subjectgastritisen_US
dc.subjectnetwork pharmacologyen_US
dc.subjectmolecular docking.en_US
dc.titleNetwork pharmacology approach to investigate the molecular mechanism of DLBS2411 (Cinnamomum burmannii) as a gastritis treatmenten_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
japs2024v14n9p255.pdf
Size:
1.37 MB
Format:
Adobe Portable Document Format
Download
Collections
Journal of Applied Pharmaceutical Science (JAPS)